��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2003, 29(5) 285-287 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	��о�
	��
	��
	֣��
	PubMed
	Article by
	Article by

��м��ض��۷��Ӧ�õĻع�

��, ֣��

�й�Э��ҽ�ƴ�ѧ��й�ҽѧ��ѧԺƤ��о�� Ͼ� 210042

ժҪ��

�ع��м��ض��۵ĸ��ַ��,��ֶεĲ�ͬ,��۷��Է��ࡣͬʱ�ܽ��м��ҩ��ٴ��о��һ��ٴ��Ч�۲�Ĳ��,ѡ��ʹ��ض��۷��Ĳ�ͬ��ѡ��ݡ�

�ؼ���� м�� о�

Abstract:

Keywords:

�ո�� 2003-03-20 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Harari M,Shani J,Hristakieva E,et al.Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score(PASS),and its comparison with the classic method of Psoriasis Area and Severity Index(PASI),before and after climatotherapy at the Dead-Sea.Int J Dermatol,2000,39(12):913-918.
[2] Krueger GG,Feldman SR,Camisa C,et al.Two considerations for patients with psoriasis and their clinicians:what defines mild,moderate,and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol,2000,43(2 Pt 1):281-285.
[3] Feldman SR,Fleischer AB Jr,Reboussin DM,et al.The self-administered psoriasis area and severity index is valid and reliable.J Invest Dermatol,1996,106(1):183-186.
[4] Jemec GB,Wulf HC.The applicability of clinical scoring systems:SCORAD and PASI in psoriasis and atopic dermatitis.Acta Derm Venereol,1997,77(5):392-393.
[5] Kirby B,Fortune DG,Bhushan M,et al.The Salford Psoriasis Index:an holistic measure of psoriasis severity.Br J Dermatol,2000,142(4):728-732.
[6] Mckenna KE,Stern RS.The outcomes movement and new measures of the severity of psoriasis.J Am Acad Dermatol,1996,34(3):534-538.
[7] Fortune DG,Main CJ,O'Sullivan TM,et al.Quality of life in patients with psoriasis:the contribution of clinical variables and psoriasis-specific stress.Br J Dermatol,1997,137(5):755-760.
[8] Savolainen L,Kontinen J,Roning J,et al.Application of machine vision to assess involved surface in patients with psoriasis.Br J Dermatol,1997,137(3):395-400.
[9] Savolainen L,Kontinen J,Alatalo E,et al.Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis.Acta Derm Venereol,1998,78(6):466-467.
[10] De Pita O,Ruffelli M,Cadoni S,et al.Psoriasis:comparison of immunological markers in patients with acute and remission phase.J Dermatol Sci,1996,13(2):118-124.
[11] Zachariae R,Zachariae H,Blomqvist K,et al.Quality of life in 6497 Nordic patients with psoriasis.Br J Dermatol,2002,146(6):1006-1016.
[12] Weiss SC,Kimball AB,Liewehr DJ,et al.Quantifying the harmful effect of psoriasis on health-related quality of life.J Am Acad Dermatol,2002,47(4):512-518.
[13] Harvima RJ,Viinamaki H,Harvima IT,et al.Association of psychic stress with clinical severity and symptoms of psoriatic patients.Acta Derm Venereol,1996,76(6):467-471.